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Carcinoma NOS is a Common Histologic Diagnosis and is
Increasing in Proportion Among Non-small Cell Lung
Cancer Histologies
Sai-Hong Ignatius Ou, MD, PhD,*†‡ and Jason A. Zell, DO, MPH*†‡
Background: Recent clinical trials have demonstrated differential
survival benefit from chemotherapy regimens according to non-
small cell lung cancer (NSCLC) histology. We investigated whether
the distribution of carcinoma NOS (not otherwise specified) among
NSCLC cases in California have changed over time and determined
the prognostic significance of carcinoma NOS.
Methods: Retrospective population-based study of 175,298 NSCLC
patients diagnosed histologically or cytologically from the statewide
California Cancer Registry from 1989 to 2006.
Results: Carcinoma NOS accounted for 22.1% of all NSCLC
patients, was the most commonly diagnosed cytologically (37.0%),
and had the poorest 5-year survival estimates (5.8%) and median
overall survival (OS, 5 months) among all NSCLC histologies. The
proportion of carcinoma NOS had increased significantly from 1989
to 2006 in both males and females, in both histologically and
cytologically diagnosed NSCLC, among all four major ethnicities
(whites, African American, Hispanic, and Asian), among all age
categories, and among all American Joint Committee on Cancer
stages. The very elderly (80 years) had the highest proportion of
carcinoma NOS and cytologically diagnosed NSCLC regardless of
period of diagnosis. Cytologically diagnosed NSCLC had signifi-
cantly decreased OS than histologically diagnosed NSCLC (p 
0.0001). Cox proportional hazards regression analysis applied to stage
4 NSCLC patients indicated carcinoma NOS (vs. adenocarcinoma;
hazard ratio 1.061, 95% confidence interval 1.039–1.083, p  0.0001)
and cytologically diagnosed NSCLC (versus histologically diagnosed
NSCLC, hazard ratio 1.043, 95% confidence interval 1.024–1.062, p
0.0001) were independent unfavorable prognostic factors for OS.
Conclusions: Carcinoma NOS was a common histologic diagnosis,
had been increasing over time among NSCLC, and carried an
independent unfavorable prognosis among stage 4 NSCLC patients.
Key Words: Carcinoma NOS, Fine-needle aspiration, Non-small
cell lung cancer, Very elderly patients, Cytologically diagnosed
NSCLC, California Cancer Registry.
(J Thorac Oncol. 2009;4: 1202–1211)
Lung cancer is the leading cause of cancer incidences andmortality worldwide.1 Without a validated screening
method, most NSCLC are diagnosed at an advanced stage.
Treating advanced stage lung cancer remains a challenging
endeavor with median overall survival (OS) of stage 4 disease
to be around 10 to 12 months from modern treatment trials.
Until a few years ago, the standard of care for first-line
treatment of NSCLC was a doublet chemotherapy regimen.2
Eastern Cooperative Oncology Group (ECOG) 4599, a trial
using histology as one of the eligibility criteria, led to the
approval of bevacizumab in combination of carboplatin and
paclitaxel for the first-line treatment of nonsquamous
NSCLC.3 The exclusion of squamous cell carcinoma histol-
ogy from E4599 was due to a preceding phase II dose-finding
trial that increased fatal hemoptysis in patients with squa-
mous cell carcinoma histology.4 Another recent published
trial using histology as a predefined analysis criterion dem-
onstrated that the combination of cisplatin and pemetrexed
resulted in statistically superior survival in adenocarcinoma
and large cell carcinoma but not in squamous cell carcinoma
when compared with the combination of cisplatin and gem-
citabine.5 A retrospective analysis of pemetrexed versus do-
cetaxel trial in second-line treatment of NSCLC revealed
inferior survival of squamous cell carcinoma patients who
received pemetrexed when compared with docetaxel (6.2 vs.
7.4 months, respectively, adjusted hazard ratio [HR] 1.56,
95% confidence internval [CI] 1.08–2.26).6 These two stud-
ies5,6 resulted in the approval of the cisplatin and pemetrexed
in the first-line treatment of nonsquamous NSCLC and the
restriction of single-agent pemetrexed in the second-line
treatment to nonsquamous NSCLC only. These studies have
ushered in using NSCLC histology as a key determinant in
choosing a treatment regimen for advanced NSCLC.7
Thus, medical oncologists are now faced with a daily
decision to select chemotherapy treatment according to the
histology of NSCLC. However, occasionally the pathology
report does not report the diagnosis of lung cancer beyond
non-small cell carcinoma or poorly-differentiated carcinoma.
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In this report using the California Cancer Registry (CCR)
database, we investigated whether the proportion of carci-
noma NOS (not otherwise specified) among NSCLC has
changed over time and whether the method of pathologic
diagnosis (histologic or cytologic) affects the proportion of
carcinoma NOS and determined the prognostic significance
of carcinoma NOS in advanced NSCLC.
MATERIALS AND METHODS
Population
This was a retrospective study involving analysis of
data from the statewide CCR. NSCLC patients diagnosed
between 1989 and 2006 with complete follow-up data were
included in the study. Only histologically or cytologically
diagnosed NSCLC cases were included in the analysis.8 The
histology category of carcinoma NOS was abstracted by
examining histologic codes that did not further classify
NSCLC into adenocarcinoma, bronchioloalveolar carcinoma
(BAC), squamous cell, large cell carcinoma, or mixed/other
histology. The ICD-0-3 codes 8000, 8010, 8020, 8021, and
8046 were used to define carcinoma NOS in this study.
American Joint Committee on Cancer (AJCC) stages
were derived according to the AJCC 6th edition staging
system using available clinical and pathologic TNM data
from the cancer registry before 2002 and from Surveillance,
Epidemiology, and End Results (SEER) AJCC summary
staging from 2002 onwards. Patient demographic data includ-
ing age, ethnicity, gender, marital status, surgery, and radia-
tion were abstracted using SEER codes. Chemotherapy given
during the first course of therapy was obtained using CCR
codes. The measurement of socioeconomic status used in this
analysis was a composite measure using CCR and census data
as previously described.8 The last date of follow-up was
either the date of death or the last date the patient was
contacted.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for NSCLC patients, using Pearson 2
statistic for nominal variables and Student t test for continu-
ous variables. Comparison of nonparametric values across
two groups were done using Wilcoxon rank sum test. Uni-
variate survival rate analyses were estimated using Kaplan-
Meier method, with comparisons made between groups by
the log-rank test. Cox proportional hazards modeling using
time since diagnosis were performed. All statistical analyses
were conducted using SAS 9.1 statistical software (SAS
Institute, Inc., Cary, NC). Statistical significance was as-
sumed for a two-tailed p value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (IRB no. 2007–6078).
RESULTS
Between 1989 and 2006, 175,298 patients with histolog-
ically or cytologically confirmed NSCLC were included in the
analysis. The median age of all the patients was 69 years (95%
CI 48–84) and the median follow-up time was 7 months (range
0–222). Of the patients diagnosed, 13.8%were 80 years or older
and the age category of 70 to 79 years of age represented the
highest percentage (33.4%) among all age categories.
Patient Characteristics by Histology
Carcinoma NOS made up of 22.1% of all NSCLC. BAC
patients had the longest median follow-up time (25 months),
whereas carcinoma NOS patients had the shortest (5 months).
There were more male patients than female patients
among all the histologies except for BAC where 58.1% of the
patients were female. Carcinoma NOS was most commonly
diagnosed cytologically (37.0%), whereas BAC was the least
commonly diagnosed cytologically (6.7%) among all the
histologies. Additionally, patients with carcinoma NOS pre-
sented with highest proportion of stage 4 disease (44.7%) and
the highest proportion of unknown tumor differentiation
(59.2%). The clinicopathologic characteristics according to
individual histology are listed in Table 1.
Period of Diagnosis
The study period was evenly divided into three periods
of 6 calendar years each (period 1: 1989–1994; period 2:
1995–2000; and period 3: 2001–2006). The proportion of
NSCLC patients diagnosed histologically compared with that
of cytologically was also relatively constant among the three
periods. However, the median age of the patients increased
significantly from 68 to 70 years of age over time. The
proportion of the five major histologies plotted individually
by period of diagnosis is shown in Figure 1.
The proportion of carcinoma NOS among NSCLC
increased significantly from 15.8% in period 1 to 22.0% in
period 2 to 29.0% in period 3, whereas conversely squamous
cell carcinoma and large cell carcinoma decreased signifi-
cantly. Smaller increases in the proportion of adenocarci-
noma and BAC were also observed. We then compared the
changes in the proportions of carcinoma NOS with time
across specific clinical variables. There were significant in-
creases in carcinoma NOS from period 1 to period 3 in both
males and females (Fig. 2A), among the four ethnicities
(whites, Hispanic, African American, and Asian) (Fig. 2B),
among all age categories (Fig. 2C), among all AJCC stages
(Fig. 2D), and in both histologically and cytologically diag-
nosed NSCLC (Fig. 2E). The complete clinicopathologic
characteristics of NSCLC patients diagnosed among the three
periods are listed in Table 2.
Method of Diagnosis
About one-quarter (25.2%) of the patients was diagnosed
cytologically and this proportion remained fairly constant through-
out the three periods: period 1 (23.7%), period 2 (27.0%), and
period 3 (25.2%). The median age of cytologically diagnosed
NSCLC patients was significantly older than histologically
diagnosed NSCLC patients (71 vs. 68 years, p  0.0001).
Furthermore, 19.4% of cytologically diagnosed patients
were the very elderly (80 years) compared with 11.9% of
histologically diagnosed patients (p  0.0001). The me-
dian follow-up time for cytologically diagnosed NSCLC
was significantly shorter than histologically diagnosed
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TABLE 1. Characteristics of the Major NSCLC Histologies From 1989 to 2006
Histology
AdenoCA SqCC BAC LCC
Carcinoma
NOS Other/Mixed p
N (%) 67,133 (38.3) 46,253 (26.4) 7786 (4.4) 14,321 (8.2) 38,817 (22.1) 988 (0.6)
Median age of diagnosis (yr)
(95% quantile)
67 (47–84) 70 (51–84) 69 (49–84) 68 (47–84) 70 (49–85) 69 (47–85) 0.0001a
Median follow-up time (mo)
(95% quantile)
8 (0–96) 9 (0–97) 25 (0–147) 6 (0–89) 5 (0–47) 10 (0–69) 0.0001a
Period of diagnosis
1989–1994 22,676 (33.8) 18,550 (40.1) 2488 (32.0) 7004 (48.9) 9570 (24.7) 139 (14.1) 0.0001
1995–2000 22,513 (33.5) 15,399 (33.3) 2603 (33.4) 4779 (33.4) 12,849 (33.1) 202 (20.5)
2001–2006 21,944 (32.7) 2695 (34.6) 2695 (34.6) 2538 (17.7) 16,398 (42.2) 647 (65.5)
Method of diagnosis
Histologic 50,168 (74.7) 37,533 (81.2) 7266 (93.3) 10,677 (74.6) 24,459 (63.0) 925 (93.6) 0.0001
Cytologic 16,965 (25.3) 8700 (18.8) 520 (6.7) 3644 (25.4) 14,358 (37.0) 63 (6.4)
Age (yr)
0–39 789 (1.2) 196 (0.4) 70 (0.9) 139 (1.0) 296 (0.8) 14 (1.4) 0.0001
40–49 4382 (6.5) 1491 (3.2) 367 (4.7) 867 (6.1) 1945 (5.0) 58 (5.9)
50–59 12,388 (18.5) 5892 (12.7) 1173 (15.1) 2464 (17.2) 6049 (15.6) 153 (15.5)
60–69 20,807 (31.0) 14,755 (31.9) 2379 (30.6) 4418 (30.9) 11,099 (28.6) 277 (28.0)
70–79 20,436 (30.4) 17,337 (37.5) 2780 (35.7) 4648 (32.5) 13,070 (33.7) 326 (33.0)
80 8331 (12.4) 6582 (14.2) 1017 (13.1) 1785 (12.5) 6358 (16.4) 160 (16.2)
Gender
Male 35,053 (52.2) 30,358 (65.6) 3262 (41.9) 8315 (58.1) 22,046 (56.8) 509 (51.5) 0.0001
Female 32,080 (47.8) 15,985 (34.4) 4524 (58.1) 6006 (41.9) 16,771 (43.2) 479 (48.5)
Ethnicity
Whites 50,033 (74.5) 35,416 (76.6) 5671 (72.8) 10,899 (76.1) 28,891 (74.4) 737 (74.6) 0.0001
African American 5002 (7.5) 4179 (9.0) 524 (6.7) 1170 (8.2) 3294 (8.5) 60 (6.1)
Hispanic 5737 (8.6) 3620 (7.8) 706 (9.0) 1230 (8.6) 3337 (8.6) 99 (10.0)
Asian 6089 (9.1) 2802 (6.1) 865 (11.1) 982 (6.9) 3069 (7.9) 91 (9.2)
American Indian/other 272 (0.4) 236 (0.5) 20 (0.3) 40 (0.3) 226 (0.6) 1 (0.1)
AJCC stage
1 9798 (14.6) 7767 (16.8) 3209 (41.2) 1532 (10.7) 2213 (5.7) 247 (25.0) 0.0001
2 2795 (4.2) 3004 (6.5) 414 (5.3) 556 (3.9) 811 (2.1) 84 (8.5)
3 12,195 (18.2) 10,115 (21.9) 738 (9.5) 2695 (18.8) 7102 (18.3) 146 (14.8)
4 26,223 (39.1) 10,758 (23.3) 1398 (18.0) 5186 (36.2) 17,341 (44.7) 229 (23.2)
Unknown 16,122 (24.0) 14,609 (31.6) 2027 (26.0) 4352 (30.4) 11,350 (29.2) 282 (28.5)
Histologic differentiation
Well 3060 (4.6) 1608 (3.5) 2214 (28.4) 21 (0.2) 94 (0.2) 90 (9.1) 0.0001
Moderate 12,167 (18.1) 11,887 (25.7) 1893 (24.3) 74 (0.5) 392 (1.0) 138 (14.0)
Poor 25,204 (37.5) 18,257 (39.5) 652 (8.4) 3840 (26.8) 12,741 (32.8) 317 (32.1)
Undifferentiated 940 (1.4) 735 (1.6) 57 (0.7) 6517 (45.5) 2624 (6.8) 113 (11.4)
Unknown 25,762 (38.4) 13,765 (29.8) 2970 (38.2) 3888 (27.0) 22,966 (59.2) 330 (33.4)
Socioeconomic status
SES1 9807 (14.6) 8911 (19.3) 975 (12.5) 2577 (18.0) 6380 (16.4) 105 (10.6) 0.0001
SES2 13,585 (20.2) 10,516 (22.7) 1411 (18.1) 3185 (22.2) 8492 (21.9) 194 (19.6)
SES3 14,765 (22.0 10,479 (22.7) 1637 (21.0) 3254 (22.7) 8841 (22.8) 196 (19.8)
SES4 14,686 (21.9) 9179 (19.9) 1848 (23.7) 2958 (20.7) 8160 (21.0) 247 (25.0)
SES5 14,290 (21.3) 7168 (15.5) 1915 (24.6) 2347 (16.4) 6944 (17.9) 246 (24.9)
Marital status
Unmarried 27,316 (40.7) 19,931 (43.1) 3076 (39.5) 6063 (42.3) 17,157 (44.2) 397 (40.2) 0.0001
Married 28,262 (57.0) 25,158 (54.4) 4569 (58.7) 7919 (55.3) 20,503 (52.8) 575 (58.2)
Unknown 1555 (2.3) 1164 (2.5) 141 (1.8) 339 (2.4) 1157 (3.0) 16 (1.6)
(Continued)
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NSCLC (5 vs. 9 months, p  0.0001). The tumor differ-
entiation of 68.7% of the cytologically diagnosed NSCLC
cases was unknown compared with only 30% of histolog-
ically diagnosed NSCLC cases.
Among the three major histologies (adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma) the vast
of majority (90%) of early stage (stages 1 and 2) disease
was diagnosed histologically compared with 25 to 35% of the
advanced stage disease. Of note, less than 2% of early stage
(stages 1 and 2) BAC was diagnosed cytologically (Table 3).
However, the percentages of carcinoma NOS diagnosed cy-
tologically remained high (between 25 and 40%) regardless
of AJCC stages. The clinicopathologic characteristics of the
patients diagnosed histologically and cytologically are listed
in supplemental Table 1 (see Supplemental Digital Content 1,
http://links.lww.com/JTO/A7).
Very Elderly Patients (80 years)
The proportion of NSCLC patients who were the
very elderly (80 years) increased significantly from
10.8% (period 1) to 17.1% (period 3) in California (Table
2). Additionally, these patients had the highest proportion
of carcinoma NOS (26.2%) among all age categories, and
this proportion had increased from 19.9% (period 1) to
25.7% (period 2) to 31.0% (period 3). Furthermore, the
proportion of NSCLC diagnosed cytologically was the
highest among the very elderly regardless of period of
diagnosis. The proportion of patients diagnosed cytologi-
cally or histologically stratified by age category and period
of diagnosis is listed in Table 4.
Univariate Survival Analysis
BAC histology had the highest 5-year survival esti-
mate and median OS (39.0% and 36 months, respectively),
followed closely by adenocarcinoma (13.8% and 8 months,
respectively) and squamous cell carcinoma (13.3% and 9
months, respectively), then large cell carcinoma (9.7% and
6 months, respectively), and carcinoma NOS (5.8% and 5
months, respectively). Patients with histologically diag-
FIGURE 1. Percentage of individual NSCLC his-
tology by periods of diagnosis.
TABLE 1. (Continued)
Histology
AdenoCA SqCC BAC LCC
Carcinoma
NOS Other/Mixed p
Surgery
No 48,909 (72.9) 33,090 (71.5) 2604 (33.4) 11,426 (79.8) 36,068 (92.9) 414 (41.9) 0.0001
Yes 18,095 (27.0) 13,098 (28.3) 5173 (66.4) 2870 (20.0) 2588 (6.7) 573 (58.0)
Unknown 129 (0.2) 65 (0.1) 9 (0.1) 25 (0.2) 161 (0.4) 1 (0.1)
Radiation
No 40,070 (59.7) 24,326 (85.3) 6642 (85.3) 7100 (49.6) 21,450 (55.3) 733 (74.2) 0.0001
Yes 27,056 (40.3) 21,926 (47.4) 1144 (14.7) 7221 (50.4) 17,359 (44.7) 255 (25.8)
Unknown 7 (0.01) 1 (0.001) 0 (0.0) 0 (0.0) 8 (0.02) 0 (0.0)
Chemotherapy
No 44,130 (65.7) 34,447 (74.5) 6278 (80.6) 10,007 (69.9) 24,889 (64.1) 704 (71.3) 0.0001
Yes 21,532 (32.1) 10,941 (23.7) 1386 (17.8) 4036 (28.2) 12,974 (33.4) 263 (26.6)
Unknown 1471 (2.2) 865 (1.9) 122 (1.6) 278 (1.9) 954 (2.5) 21 (2.1)
a Wilcoxon rank sum test.
AdenoCA, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SqCC, squamous cell carcinoma; LCC, large cell carcinoma; NOS, not otherwise specified; SES,
socioeconomic status.
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nosed NSCLC had significant improved 5-year survival
estimate and OS (15.8% and 9 months, respectively) com-
pared to patients with cytologically diagnosed NSCLC
(3.7% and 5 months; p  0.0001).
For the most recent period of diagnosis (2001–2006),
there was greater survival benefit of chemotherapy for
stage 4 adenocarcinoma patients than stage 4 patients with
carcinoma NOS. There was a 7-month survival benefit for
adenocarcinoma patients (9 vs. 2 months) compared with a
5-month survival benefit of carcinoma patients (7 vs. 2
months).
Multivariate Survival Analysis
We performed Cox proportional hazards analysis on
all stage 4 patients to determine if individual histology and
the method of pathologic diagnosis are independent prog-
FIGURE 2. A, Percentage of carcinoma NOS according to gender by periods of diagnosis. B, Percentage of carcinoma NOS
according to four major ethnicities by periods of diagnosis. C, Percentage of carcinoma NOS according to age categories by
periods of diagnosis; D, Percentage of carcinoma NOS according to stage at diagnosis by periods of diagnosis; E, Percentage
of carcinoma NOS according to methods of diagnosis by periods of diagnosis.
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TABLE 2. Characteristics of NSCLC Patients According to Period of Diagnosis From 1989 to
2006
Period of Diagnosis
1989–1994 1995–2000 2001–2006 p
N (%)a 60,427 (34.5) 58,345 (33.3) 56,526 (32.3)
Median age of diagnosis (yr) (95% quantile) 68 (48–83) 69 (48–84) 70 (49–85) 0.0001b
Median follow-up time (mo) (95% quantile) 7 (0–142) 8 (0–98) 7 (0–49) 0.0001b
Method of diagnosis
Histologic 46,116 (76.3) 42,621 (73.1) 42,311 (74.9) 0.0001
Cytologic 14,311 (23.7) 15,724 (27.0) 14,215 (25.2)
Histology
Adenocarcinoma 22,676 (37.5) 22,513 (38.6) 21,944 (38.8) 0.0001
Bronchioloalveolar carcinoma 2488 (4.1) 2603 (4.5) 2695 (4.8)
Squamous cell carcinoma 18,550 (30.7) 15,399 (26.4) 12,304 (21.8)
Large cell carcinoma 7004 (11.6) 4779 (8.2) 2538 (4.5)
Carcinoma NOS 9570 (15.8) 12,849 (22.0) 16,398 (29.0)
Mixed/other 139 (0.2) 202 (0.3) 647 (1.1)
Age
0–39 628 (1.0) 474 (0.8) 402 (0.7) 0.0001
40–49 3377 (5.6) 2996 (5.1) 2737 (4.8)
50–59 10,121 (16.8) 9070 (15.6) 8928 (15.8)
60–69 20,564 (34.0) 17,401 (29.8) 15,770 (27.9)
70–79 19,223 (31.8) 20,334 (34.9) 19,040 (33.7)
80 6514 (10.8) 8070 (13.8) 9649 (17.1)
Gender
Male 36,326 (60.1) 32,896 (56.4) 30,321 (53.6) 0.0001
Female 24,101 (39.9) 25,449 (43.6) 26,205 (46.4)
Ethnicity
Whites 47,716 (79.0) 44,004 (75.4) 39,927 (70.6) 0.0001
African American 4949 (8.2) 4713 (8.1) 4567 (8.1)
Hispanic 4155 (6.9) 4813 (8.3) 5761 (10.2)
Asian 3367 (5.6) 4596 (7.9) 5935 (10.5)
American Indian/other 240 (0.4) 219 (0.4) 336 (0.6)
AJCC stage
Stage 1 8062 (13.3) 9174 (15.7) 7530 (13.3) 0.0001
Stage 2 3046 (5.0) 2814 (4.8) 1804 (3.2)
Stage 3 10,017 (16.6) 13,563 (23.3) 9411 (16.7)
Stage 4 16,892 (28.0) 21,098 (36.2) 23,145 (41.0)
Stage unknown 22,410 (37.1) 11,696 (20.1) 14,636 (25.9)
Histologic differentiation
Well 2335 (3.9) 2264 (3.9) 2488 (4.4) 0.0001
Moderate 9258 (15.3) 8740 (15.0) 8553 (15.1)
Poor 23,465 (38.8) 21,067 (36.1) 16,479 (29.2)
Undifferentiated 5595 (9.3) 3558 (6.3) 1734 (3.1)
Unknown 19,774 (32.7) 22,616 (38.8) 27,272 (48.3)
Socioeconomic status
SES1 10,633 (17.6) 9296 (15.9) 8826 (15.6) 0.0001
SES2 13,113 (21.7) 12,460 (21.4) 11,810 (20.9)
SES3 12,995 (21.5) 13,330 (22.9) 12,847 (22.7)
SES4 12,709 (21.0) 12,212 (20.9) 12,157 (21.5)
SES5 10,977 (18.2) 11,047 (18.9) 10,886 (19.3)
Marital status
Unmarried 24,259 (40.2) 24,684 (42.3) 24,997 (44.2) 0.0001
Married 34,576 (57.2) 32,186 (55.2) 30,224 (53.5)
Unknown 1592 (2.6) 1475 (2.5) 1305 (2.3)
(Continued)
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nostic factors. After factoring into age, gender, histologic differ-
entiation, ethnicity, period of diagnosis, socioeconomic status,
marital status, radiation, and chemotherapy; carcinoma NOS (vs.
adenocarcinoma; HR 1.061, 95% CI 1.040–1.083, p  0.0001)
and cytologically diagnosed NSCLC (vs. histologically diag-
nosed NSCLC, HR 1.043, 95% CI 1.024–10.62, p  0.0001)
are independent unfavorable prognostic factors for survival (Ta-
ble 5). Large cell carcinoma (vs. adenocarcinoma; HR 1.085,
95% CI 1.048–1.123, p  0.0001) is another unfavorable
prognostic factor.
DISCUSSION
In this report using the CCR database, we made several
observations. First, carcinoma NOS was a common histologic
diagnosis among NSCLC patients accounting for 22.1% of all
NSCLC histologies. The proportion of carcinoma NOS his-
tology was highest among the very elderly and among stage
4 patients and was significantly higher in cytologically diag-
nosed NSCLC. A study of lung cancer cases reported from
New Hampshire and Vermont hospitals between 1973 and
TABLE 2. (Continued)
Period of Diagnosis
1989–1994 1995–2000 2001–2006 p
Surgery
No 44,420 (73.5) 44,219 (75.8) 43,872 (77.6) 0.0001
Yes 15,786 (26.1) 13,983 (24.0) 12,628 (22.3)
Unknown 221 (0.4) 143 (0.3) 26 (0.05)
Radiation
No 31,164 (51.6) 33,077 (56.7) 36,080 (63.8) 0.0001
Yes 29,261 (48.4) 25,267 (43.3) 20,433 (36.2)
Unknown 2 (0.003) 1 (0.002) 13 (0.02)
Chemotherapy
No 47,562 (78.7) 39,199 (67.2) 33,697 (59.6) 0.0001
Yes 11,954 (19.8) 17,724 (30.4) 21,454 (38.0)
Unknown 911 (1.5) 1425 (2.4) 1375 (2.4)
a Percentage calculated across row.
b Wilcoxon rank sum test.
SES, socioeconomic status.
TABLE 3. Methods of Diagnosis Stratified by Histology, Period of Diagnosis, and AJCC Stage
Period of Diagnosis
1989–1994 1995–2000 2001–2006
Adenocarcinoma
AJCC stage 1 2 3 4 Unk 1 2 3 4 Unk 1 2 3 4 Unk
Histologic (%) 94.7 94.1 71.7 70.8 74.5 92.1 92.8 65.9 68.8 68.6 95.1 93.5 68.5 71.3 70.7
Cytologic (%) 5.3 5.9 28.3 29.3 25.5 7.9 7.2 34.1 31.2 31.4 4.9 6.5 31.5 28.7 29.4
Squamous cell carcinoma
AJCC stage 1 2 3 4 Unk 1 2 3 4 Unk 1 2 3 4 Unk
Histologic (%) 91.9 91.4 81.1 75.6 79.1 90.5 91.0 79.1 73.3 74.8 92.6 90.8 82.4 76.8 80.6
Cytologic (%) 8.1 8.6 18.9 24.4 20.9 9.5 9.0 20.9 26.7 25.2 7.4 9.2 17.6 23.2 19.4
Bronchioloalveolar carcinoma
AJCC stage 1 2 3 4 Unk 1 2 3 4 Unk 1 2 3 4 Unk
Histologic (%) 98.7 98.7 88.4 84.9 90.5 98.4 98.2 89.8 82.9 87.7 99.2 99.0 91.6 88.3 91.4
Cytologic (%) 1.3 1.3 11.6 15.1 9.5 1.6 1.8 10.2 17.1 12.3 0.8 1.0 8.4 11.7 8.6
Large cell carcinoma
AJCC stage 1 2 3 4 Unk 1 2 3 4 Unk 1 2 3 4 Unk
Histologic (%) 88.2 88.7 75.6 69.6 71.1 88.6 91.6 72.8 70.7 68.0 92.2 96.2 82.0 73.7 76.9
Cytologic (%) 11.8 11.3 24.4 30.4 28.9 11.4 8.4 27.2 29.3 32.0 7.8 3.8 18.0 26.3 23.1
Carcinoma NOS
AJCC stage 1 2 3 4 Unk 1 2 3 4 Unk 1 2 3 4 Unk
Histologic (%) 65.7 66.1 62.0 62.0 63.6 64.5 67.5 58.9 60.0 62.3 74.5 74.8 63.8 64.2 64.1
Cytologic (%) 34.3 33.9 38.0 38.0 36.4 35.5 32.5 41.1 40.0 37.7 25.5 25.2 36.2 35.8 35.9
Unk, unknown; AJCC, American Joint Committee on Cancer; NOS, not otherwise specified.
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1976 revealed 23.6% (235/995) of NSCLC were classified as
“other” histology.9 A study of female lung cancer patients
from the Missouri Cancer Registry between 1986 and 1991,
85 of 440 (19.3%) NSCLC cases were classified as “other.”
After simultaneous reclassification by three pathologists of
468 available lung cancer specimens, the proportion of car-
cinoma NOS among NSCLC remained at 16.7% (76/456).10
A more recent study of lung cancer diagnosed between 1993
and 1996 from the Iowa Cancer Registry (ICR), 14.7%
(50/339) of the NSCLC cases was classified as “other.”11
Thus, our data showing 22.1% all NSCLC patients presented
with carcinoma NOS is consistent with available literature.
Second, the proportion of carcinoma NOS has in-
creased significantly with time: from 15.8% (between 1989
and 1994) to 22.0% (between 1995 and 2000) and to 29.0%
(between 2001 and 2006). This increase was evident in both
males and females, among all four ethnicities, among all
AJCC stages, among all age categories, and in both histolog-
ically and cytologically diagnosed NSCLC. Reasons to ac-
count for the observed increased in the proportion of carci-
noma NOS over time are not entirely obvious. The increasing
frequency of carcinoma NOS could be associated to the increas-
ing number of small specimens obtained for lung cancer diag-
nosis especially fine-needle aspirations (FNA); however, the
proportion of NSCLC diagnosed by FNA was not available
from the CCR. The number of NSCLC patients diagnosed was
evenly distributed among the three periods with an actual small
decrease over time. The distribution of histologically (75%)
versus cytologically diagnosed (25%) NSCLC was relatively
constant with time. On the other hand, the percentage of female
TABLE 4. Method of Diagnosis and Histology by Age-Categories and Period of Diagnosis
Age Category (yr)
0–39 40–49 50–59 60–69 70–79 80
Period of diagnosis (1989–1994)
N 628 3377 10,121 20,564 19,223 6514
Method of diagnosis
Histologic (%) 542 (86.3) 2762 (81.8) 8213 (81.2) 16,260 (79.1) 14,197 (73.9) 4142 (63.6)
Cytologic (%) 86 (13.7) 615 (18.2) 1908 (18.9) 4304 (20.9) 5026 (26.2) 2372 (36.4)
Histology
Adenocarcinoma (%) 330 (52.6) 1602 (47.4) 4415 (43.6) 7715 (37.5) 6478 (33.7) 2136 (32.8)
BAC (%) 20 (3.2) 134 (4.0) 407 (4.0) 865 (4.2) 811 (4.2) 251 (3.9)
SqCC (%) 101 (16.1) 638 (18.9) 2484 (24.5) 6618 (32.2) 6627 (34.5) 2082 (32.0)
LCC (%) 69 (11.0) 482 (14.3) 1254 (12.4) 2345 (11.4) 2120 (11.0) 734 (11.3)
Carcinoma NOS (%) 101 (16.1) 510 (15.1) 1541 (15.2) 2980 (14.5) 3144 (16.4) 1294 (19.9)
Mixed/other (%) 7 (1.1) 11 (0.3) 20 (0.2) 41 (0.2) 43 (0.2) 17 (0.3)
Period of diagnosis (1995–2000)
N 474 2996 9070 17,401 20,334 8070
Method of diagnosis
Histologic (%) 390 (82.3) 2359 (78.7) 7018 (77.4) 13,245 (76.1) 14,575 (71.7) 5034 (62.4)
Cytologic (%) 84 (17.7) 637 (21.3) 2052 (22.6) 4156 (23.9) 5759 (28.3) 3036 (37.6)
Histology
Adenocarcinoma (%) 244 (51.5) 1443 (48.2) 4034 (44.5) 6895 (39.6) 7137 (35.1) 2760 (34.2)
BAC (%) 24 (5.1) 121 (4.0) 363 (4.0) 747 (4.3) 1028 (95.1) 320 (4.0)
SqCC (%) 62 (13.1) 486 (16.2) 1918 (21.2) 4678 (26.9) 5988 (29.5) 2267 (28.1)
LCC (%) 52 (11.0) 268 (9.0) 777 (8.6) 1387 (8.0) 1670 (8.2) 625 (7.7)
Carcinoma NOS (%) 90 (19.9) 666 (22.2) 1943 (21.4) 3642 (20.9) 4437 (21.8) 2071 (25.7)
Mixed/other (%) 2 (0.4) 12 (0.4) 35 (0.4) 52 (0.3) 74 (0.4) 27 (0.3)
Period of diagnosis (2001–2006)
N 402 2737 8928 15,770 19,040 9649
Method of diagnosis
Histologic (%) 323 (80.4) 2152 (78.6) 6946 (77.8) 12,241 (77.6) 14,190 (74.5) 6459 (66.9)
Cytologic (%) 79 (19.7) 585 (21.4) 1982 (22.2) 3529 (22.4) 4850 (25.5) 3190 (33.1)
Histology
Adenocarcinoma (%) 215 (53.5) 1337 (48.9) 3939 (44.1) 6197 (39.3) 6821 (35.8) 3435 (35.6)
BAC (%) 26 (6.5) 112 (94.1) 403 (4.5) 767 (4.9) 941 (4.9) 446 (4.6)
SqCC (%) 33 (8.2) 367 (913.40) 1490 (16.7) 3459 (21.9) 4722 (24.8) 2233 (23.1)
LCC (%) 18 (4.5) 117 (4.3) 433 (4.9) 686(4.4) 858 (4.5) 426 (4.4)
Carcinoma NOS (%) 105 (26.1) 769 (28.1) 2565 (28.7) 4477 (28.4) 5489 (28.8) 2993 (31.0)
Mixed/other (%) 5 (1.2) 35 (1.3) 98 (1.1) 184 (1.2) 209 (1.1) 116 (1.2)
BAC, bronchioloalveolar carcinoma; SqCC, squamous cell carcinoma; LCC, large cell carcinoma; NOS, not otherwise specified.
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NSCLC patients diagnosed increased from 39.9% to 46.4% so
were the percentages of Asian and Hispanic patients which
increased from 5.6% to 10.6% and from 6.9% to 10.2%, respec-
tively. However, the proportion of carcinoma NOS among
female patients was similar to that of male patients and the
proportion of carcinoma NOS among Asian and Hispanic pa-
tients were similar to that of whites and African American
patients. Thus, the increase in female patients or Asian and
Hispanic patients over time could not account for the observed
increase in proportion of carcinoma NOS. The proportion of
stage 4 patients increased from 28.0 to 41.0% over time (Table
2). Median age of the patients increased from 68 to 70 years with
time as did the proportion of the very elderly (from 10.8 to
17.1%; Table 2). Increased proportion of stage 4 patients and the
very elderly patients could partially account for the increase in
carcinoma NOS over time as carcinoma NOS had the highest
percentage in stage 4 patients among all stages and in the very
elderly among all the age categories.
Third, carcinoma NOS patients had the poorest survival
among major NSCLC histologies, and carcinoma NOS is an
independent poor prognostic factor for survival among stage
4 patients by multivariate analysis. Additionally, we demon-
strated in this study that carcinoma NOS patients derived less
survival benefit from chemotherapy than adenocarcinoma
patients during the most recent period of diagnosis. Consis-
tent with this observation, subgroup analysis of ECOG 4599
trial indicated that patients with carcinoma NOS did not
derive additional survival benefit from the addition of bev-
acizumab to carboplatin and paclitaxel chemotherapy regi-
men as opposed to adenocarcinoma and large cell carcinoma
patients.12 The poor survival of carcinoma NOS could be
associated with poorer tumor differentiation, and therefore,
more aggressive tumor biology of these tumors. As shown in
Table 1, the proportion of poorly differentiated tumor among
carcinoma NOS was 32.8%, which was less than that of
poorly differentiated tumor among adenocarcinoma (37.5%)
or squamous cell carcinoma (39.5%). However, the propor-
tion of tumor of unknown differentiation was highest among
carcinoma NOS. Additionally, our multivariate analysis re-
vealed an independently increased mortality risk for carci-
noma NOS versus adenocarcinoma after adjustment for tu-
mor differentiation and other clinical factors. Now with
chemotherapy regimens that can be tailored according to
histology,3,5,6 being able to further classify carcinoma NOS
may result in improved survival outcomes. There are now
emerging molecular diagnostic methods to classify NSCLC
into squamous and nonsquamous histology from formalin-
fixed paraffin-embedded tissue slide.13
Fourth, our study indicates that very elderly patients
and stage 4 patients had the highest proportion of cytologi-
cally diagnosed NSCLC, suggesting the least invasive
method may have been employed to arrive at the NSCLC
diagnosis in these circumstances. Thus, there may have been
insufficient tumor material to further subclassify NSCLC
resulting in a high proportion of carcinoma NOS among these
two patient groups. Currently, a second rebiopsy for more
tissue to further classify the tumor is not customarily done
when a primary diagnosis of NSCLC has been established,
especially in the very elderly or in patients with advanced
disease. However, elderly patients or even performance status
2 patients do benefit from chemotherapy.14,15 Thus, accu-
rately classifying NSCLC histology will likely benefit these
elderly patients from the currently available and future che-
motherapeutic agents and enrollment into clinical trials.
Fifth, cytologically diagnosed NSCLC had significantly
decreased OS when compared to histologically diagnosed
NSCLC by univariate analysis. Furthermore, among stage 4
patients, cytologically diagnosed NSCLC was an independent
unfavorable prognostic factor. Even when histology is not the
determining factor of benefit from chemotherapy, epidermal
growth factor receptor (EGFR) copy numbers may determine
response to monoclonal antibodies directed against EGFR.16
The recent Iressa Pan-Asia Study data17 demonstrated the
presence or absence of EGFR activating mutations can de-
termine progression-free survival in never-smokers/light-
smokers receiving either oral EGFR tyrosine kinase inhibitor
or chemotherapy. Given that only approximately 60% of
never-smokers/light-smokers harbored EGFR activating mu-
tations in the Iressa Pan-Asia Study trial, having adequate
tumor tissue to test for EGFR mutations rather than clinical
profiling will be important going forward to determine the
optimal treatment strategy for never-smoker/light-smokers.
Thus, with the advent of personalized cancer care in NSCLC,
there will be increased need to test NSCLC tumor for EGFR
activating mutations, EGFR copy numbers, and other molec-
ular alterations18 to optimize treatment. Consequently,
enough tumor tissue material will have to be obtained with
TABLE 5. Cox Model of Stage 4 NSCLC Patients
Variable HR 95% CI p
Age 1.006 1.005–1.006 0.0001
Gender
Male 1.000
Female 0.858 0.843–0.873 0.0001
Histology
Adenocarcinoma 1.000
BAC 0.689 0.650–0.730 0.0001
SqCC 0.990 0.967–1.013 0.3870
LCC 1.085 1.048–1.123 0.0001
Carcinoma NOS 1.061 1.039–1.083 0.0001
Mixed/other 0.976 0.851–1.120 0.7313
Method of diagnosis
Histologic 1.000
Cytologic 1.043 1.024–1.062 0.0001
Histologic differentiation
Well differentiated 1.000
Moderately differentiated 1.174 1.101–1.252 0.0001
Poorly differentiated 1.367 1.288–1.452 0.0001
Undifferentiated 1.464 1.366–1.569 0.0001
Unknown 1.361 1.283–1.445 0.0001
Other variables included are ethnicity, period of diagnosis, socioeconomic status,
marital status, radiation, and chemotherapy.
HR, hazard ratio; CI, confidence interval; BAC, bronchioloalveolar carcinoma;
SqCC, squamous cell carcinoma; LCC, large cell carcinoma; NOS, not otherwise
specified.
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the first diagnostic biopsy to subclassify NSCLC into indi-
vidual histology and to allow molecular profiling of the
tumor. Therefore, in the future, we should strive for as few
cytologically diagnosed NSCLC cases as possible.
One limitation of the study included the lack of central
or independent pathology review. The proportion of “other”
histology from population-based registries decreased when
the original tumor specimens were available to be reviewed
by an external pathologist from 23.6% to 7.8% (73/935) from
New Hampshire and Vermont hospitals,9 from 14.7% to 9.1%
(30/329) in the ICR after independent review of available
lung cancer specimens by two pathologists.11 Carcinoma
NOS made up the majority of the postreviewed “other”
histology in the ICR study. Even though the proportion of
“other” histology decreased after review by independent
pathologists,9–11 medical oncologists in daily practice may not
have the availability of independent pathology review to further
subclassify NSCLC once the diagnosis of NSCLC is made.
Another limitation of this study was that we could not
determine the diagnostic procedure from which the tumor
tissue was obtained. Tumors obtained from surgical resection,
core biopsy, FNA could be coded as histologically diagnosed
in CCR. However, NSCLC diagnosed histologically from
FNA may not be as easily separated into individual NSCLC
histology as NSCLC diagnosed histologically from a surgical
resection samples because of limited tumor material. Even
commonly used immunohistochemistry antibody panels may
not reliably differentiated primary lung carcinoma into indi-
vidual histology from FNA samples.19 Finally, performance
status was not available from the CCR. The poorer survival of
carcinoma NOS patients may be related to poorer perfor-
mance status of these patients and subjected to less invasive
FNA procedures resulting in higher proportion of cytologi-
cally diagnosed NSCLC. This may be indirectly reflected in
the observation that the very elderly (80 years) patients had
the highest proportion of patients among patients of all age
categories with cytologically diagnosed NSCLC.
We hope our findings provide increased impetus to
diagnose NSCLC histologically with adequate tumor sam-
pling from the first diagnostic procedure. This will allow for
tumor subclassification by histology and molecular tumor
profiling, ultimately resulting in optimal treatment.
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